IT'S BACK
RECOMMENDED IN THE 2021 GUIDELINES:1
Proven efficacy and safety in various patient profiles and clinical studies:2-5
PLATO Study:
BRILINTA® 90 mg + AAS vs.
CLOPIDOGREL + AAS
Of a new CV event (CV death, AMI
or stroke) at 12 months in
patients with ACS.2
PEGASUS-TIMI 54 Study:
BRILINTA® 90 OR 60 mg + ASA vs.
PLACEBO + ASA
Of a new CV event (CV death, AMI
or stroke) after 3 years of
treatment in patients with
previous AMI.3
THEMIS Study:
BRILINTA® 60 MG + ASA
vs. PLACEBO + ASA
In the composite of CV death, AMI
or stroke at 3 years in patients
with high-risk CAD with T2D and
history of CPI.
Próximos eventos
Eventos exclusivos para profesionales de la Salud . Haga click para más información
Dislipidemia en el paciente con diabetes,
¿cómo tratarla?
Ponente: Dr. Óscar Emilio Pinzón
Día: 16 de Marzo de 2021
Horario: 19:00hs. GT
Inscríbase aquí
Dislipidemia en el paciente con diabetes,
¿cómo tratarla?
Ponente: Dr. Óscar Emilio Pinzón
Día: 16 de Marzo de 2021
Horario: 19:00hs. GT
Inscríbase aquí
Dislipidemia en el paciente con diabetes,
¿cómo tratarla?
Ponente: Dr. Óscar Emilio Pinzón
Día: 16 de Marzo de 2021
Horario: 19:00hs. GT
Inscríbase aquí
Dislipidemia en el paciente con diabetes,
¿cómo tratarla?
Ponente: Dr. Óscar Emilio Pinzón
Día: 16 de Marzo de 2021
Horario: 19:00hs. GT
Inscríbase aquí
IT'S BACK
Abbreviations: AHA: American Heart Association; ACC: American College of Cardiology; SCAI: Society for Cardiovascular Angiography and Interventions; ACS: Acute coronary syndrome; AMI: Acute myocardial infarction; CAD: Coronary artery disease; PEGASUS: Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin; PLATO: Platelet inhibition and patient Outcomes; IPC: Percutaneous coronary intervention; T2D: Type 2 Diabetes; RRR: Relative risk reduction; TIMI: Thrombolysis in myocardial infarction.
References: 1. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2022;79(2):e21-e129. 2. Wallentin L, Becker RC, Budaj A, et al; for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057. [+ Supplementary Appendix]. 3. Bonaca MP, Bhatt DL, Cohen M, et al; for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-1800. 4. Steg PG, Bhatt DL, Simon T, et al; for the THEMIS Steering Committee and Investigators. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381(14):1309-1320. 5. Bhatt DL, Steg PG, Mehta SR, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019;394(10204):1169-1180. doi:10.1016/S0140-6736(19)31887-2.
Produced by AstraZeneca CAMCAR Costa Rica S.A., Roble Corporate Center, 5th floor, Escazú, San José Costa Rica, phone: (506) 2201-3400, P.O. Box: 993-1260 Escazú. www.camcar.astrazeneca.com for AstraZeneca CAMCAR S.A. To report an adverse event, quality complaints or medical information, visit: https://www.contactazmedical.astrazeneca.com - Exclusive material for health professionals. CC-11987 June / 2026
Scan this QR code to
see the product IPP